Wall Street analyst estimates for PTC Therapeutics, Inc. (PTCT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.29 | ||
| 2026-07-30 | $0.92 | $0.24 | +289.3% |
| 2026-05-07 | $-0.03 | $-0.45 | +93.3% |
| 2026-02-19 | $-1.67 | $-0.21 | -695.2% |
| 2025-11-04 | $0.20 | $-1.19 | +116.8% |
| 2025-08-07 | $-0.83 | $-1.07 | +22.4% |
| 2025-05-06 | $10.04 | $-1.08 | +1029.6% |
| 2025-02-27 | $-0.85 | $-1.12 | +24.1% |
Valuation Ratios
| Price / Book | -33.74 |
| EV / EBITDA | 30.47 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Cost of Revenue | $117.6M | $4.6M | $12.7M | $12.1M | $18.9M | $32.3M | $44.7M | $65.5M | $57.4M | $71.8M |
| Gross Profit | -$34.9M | $189.8M | $252.1M | $294.8M | $361.8M | $506.3M | $654.1M | $872.3M | $749.4M | $1.66B |
| Research & Development | $117.6M | $117.5M | $172.0M | $257.5M | $477.6M | $540.7M | $651.5M | $666.6M | $534.5M | $455.2M |
| Selling, General & Admin | $97.1M | $121.3M | $153.5M | $202.5M | $245.2M | $285.8M | $326.0M | $332.5M | $300.9M | $347.1M |
| Operating Expenses | $214.8M | $254.1M | $348.4M | $536.0M | $793.6M | $880.7M | $1.10B | $1.31B | $1.05B | $802.4M |
| Operating Income | -$132.1M | -$64.3M | -$115.7M | -$241.2M | -$431.8M | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $856.5M |
| EBITDA | -$128.8M | -$46.6M | -$89.5M | -$195.3M | -$303.1M | -$368.2M | -$367.8M | -$330.3M | -$120.5M | $887.7M |
| Interest Expense | $8.3M | $12.1M | $12.6M | $12.5M | $56.4M | $86.0M | $90.9M | $129.2M | $167.0M | $152.2M |
| Pre-tax Income | -$141.5M | -$77.7M | -$128.1M | -$239.9M | -$402.9M | -$518.3M | -$587.5M | -$696.1M | -$363.1M | $696.6M |
| Income Tax | $569000 | $1.3M | -$29000 | $11.7M | $35.2M | $5.6M | -$28.5M | -$69.5M | $176000 | $14.0M |
| Net Income | -$142.1M | -$79.0M | -$128.1M | -$251.6M | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| EPS | $-4.17 | $-2.02 | $-2.75 | $-4.27 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $8.58 |
| EPS (Diluted) | $-4.17 | $-2.02 | $-2.75 | $-4.27 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $7.78 |
| Shares Outstanding (Diluted) | $34.0M | $39.2M | $46.6M | $58.9M | $66.0M | $70.5M | $71.7M | $74.8M | $76.8M | $88.3M |
Price
| Price | $67.30 |
| Market Cap | $5.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks